ArticleScientific reports2017
Use of the relative release index for histamine in LAD2 cells to evaluate the potential anaphylactoid effects of drugs.
Article in Scientific reports, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed, 51 citations in OpenAlex.
- The Anaphylactic and Anti-allergenic Properties of Shuanghuanglian: A Review.Combinatorial chemistry & high throughput screening · 2026Review
- Advances in MRGPRX2-mediated anaphylactoid reactions to traditional Chinese medicine injections.Frontiers in pharmacology · 2025Review
- Plasma MRGPRX2 Correlates with Severity of Artemisia-Induced Allergic Rhinitis, Particularly in IgE-Negative Patients: A Cross-Sectional Study.Journal of asthma and allergy · 2025Article
- "Relative symmetry with electronegativity of different key-groups" strategy for MRGPRX2 antagonist design and its effect on antigen-induced pulmonary inflammation.Acta pharmaceutica Sinica. B · 2025Article
- Amphotericin B for injection triggers degranulation of human LAD2 mast cells by MRGPRX2 and pseudo-allergic reactions in mice via MRGPRB2 activation.Immunologic research · 2024Article
- Modulation of the Mas-Related G Protein-Coupled Receptor X2 (MRGPRX2) by Xenobiotic Compounds and Its Relevance to Human Diseases.Journal of xenobiotics · 2024Review
- MrgX2-SNAP-tag/cell membrane chromatography model coupled with liquid chromatography-mass spectrometry for anti-pseudo-allergic compound screening in Arnebiae Radix.Analytical and bioanalytical chemistry · 2022Article
- Mas-Related G Protein-Coupled Receptor-X2 and Its Role in Non-immunoglobulin E-Mediated Drug Hypersensitivity.Immunology and allergy clinics of North America · 2022Review
- Ligands and Signaling of Mas-Related G Protein-Coupled Receptor-X2 in Mast Cell Activation.Reviews of physiology, biochemistry and pharmacology · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors at 3 institutions in 2 countries.
Funding
Abstract
Anaphylactoid reactions are common clinical acute adverse drug reactions that can exacerbate a patient's condition and produce effects that may become life-threatening. Therefore, it is important to establish a novel method to evaluate drugs for anaphylactoid reactions. In this study, we developed a sensitive and rapid method to detect histamine release from LAD2 cells using liquid chromatography-tandem mass spectrometry (LC-MS/MS) and constructed a relative release index based on various release curve parameters, including allergen release time and sudden change rate, to evaluate the potential and strength of allergen-induced anaphylactoid reactions. This LAD2 release model was used to evaluate anaphylactoid reactions induced by ciprofloxacin, norfloxacin, lomefloxacin, moxifloxacin, and baicalin. The results positively correlated with those obtained with an Evans blue ear test and negatively correlated with the Ca
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.